Neurogene to Participate in Upcoming Investor Conferences

Neurogene’s two conference talks will be available as live webcasts.

HC Wainwright & Co. Reiterates Buy on Neurogene, Maintains $65 Price Target

Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome

Neurogene To Present Data Related To NGN-401 Gene Therapy Program For Rett Syndrome At ESGCT 33rd Annual Congress; New Preclinical Data Expected To Further Validate NGN-401’s Differentiated Design

Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress

Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?

Should I buy NEUROGENE INC (NGNE)

$NGNE stock is down 10% today. Here's what we see in our data.

JP Morgan Initiates Coverage On Neurogene with Overweight Rating, Announces Price Target of $60

Neurogene stock a new Overweight at J.P. Morgan (NGNE:NASDAQ)

Neurogene 13G Filing Shows Jennison Associates Reports 11.1% Stake In Co. As Of Sept. 30

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Neurogene Inc. Announces Pricing of $125 Million Public Offering